A Cell-Based HTS to Discover Molecules that Inhibit VEEV Replication
A Cell-Based HTS to Discover Molecules that Inhibit VEEV Replication
批准号:
8209084
负责人:
Donghoon Chung
金额:
$3.74万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2011
资助国家:
美国
项目状态:
已结题
起止时间:
2011-01-01 至 2013-04-30
关键词:
AerosolsAlphavirusAlphavirus InfectionsAnimal ModelAntiviral AgentsAttenuatedBase PairingBiochemicalBiological AssayCategoriesCell DeathCell SurvivalCellsCenters for Disease Control and Prevention (U.S.)ChemicalsCollaborationsCulicidaeDiseaseDockingDoseEpidemicEquus caballusEscherichia coliEvaluationFDA approvedGenesGoalsHumanImageIn VitroInhibitory Concentration 50LibrariesLuc GeneMeasuresMedicalMethodsMilitary PersonnelModelingMolecularMolecular BankMutationNational Institute of Allergy and Infectious DiseaseOutcomePathway interactionsPeptide HydrolasesPhylogenetic AnalysisPolymerase Chain ReactionProcessProphylactic treatmentProteinsPublic HealthReadingReporterReportingResearchScreening procedureSeriesSouth AmericaSpecificitySystemTestingTherapeuticTimeToxic effectUnited States National Institutes of HealthUniversitiesValidationVenezuelan Equine Encephalitis VirusViralViral PhysiologyViral ProteinsViral load measurementVirusVirus DiseasesVirus ReplicationWestern Equine Encephalitis VirusWorkanti-viral efficacybasebiodefensecytotoxicitydrug discoveryefficacy testingepizooticfluoromethyl 2,2-difluoro-1-(trifluoromethyl)vinyl etherfollow-upgenome sequencinghigh throughput screeningin vivoinhibitor/antagonistluminescencenovelprogramspublic health relevancerepositoryresponsescaffoldsmall moleculetransmission processweapons
中文摘要
描述(由申请人提供):该项目旨在通过利用分子图书馆计划中心网络(MLPCN)的高通量筛选(HTS)活动,发现具有抑制委内瑞拉马脑炎病毒(VEEV)复制活性的小分子。VEEV是一种脑病甲病毒,因其在流行病期间引起严重疾病的能力以及潜在的生物恐怖武器用途而被列为精选制剂。然而,目前还没有fda批准的veev相关疾病的治疗或预防方法。由于处理药剂的限制,筛选药剂的抗病毒药物发现是不切实际的。通过开发基于弱毒VEEV菌株TC-83的稳健细胞病变效应(CPE)检测,在实现有效治疗目标方面取得了进展。减毒菌株不是选择剂,可以在BSL-2实验室处理。由于减毒菌株的基因组序列与野生型VEEV具有显著的高同源性,我假设通过该试验筛选的抗病毒化合物对野生型VEEV也有活性。因此,实现特定目标的结果将可作为从分子文库小分子库(MLSMR)文库中发现活性化合物的主要筛选和后续研究,以验证减毒型和野生型病毒株的活性。第一个具体目标将是筛选MLSMR文库,使用经过验证的基于细胞的检测方法来测量由VEEV引起的CPE,菌株TC-83作为主要HTS。第二个具体目标将是通过两种方式验证从初级筛选中选择的化合物:1)剂量反应细胞毒性和功效试验;2)与野生型相似度更高的第二种减毒菌株V3526重新筛选。最后,将提供第三组分析,这些分析对于开发和表征化学探针至关重要。选定的化合物随后将使用野生型菌株V3000的滴度降低试验进行验证。最后,对于选择作为探针的化合物,将进行基于报告基因的分子和生化分析的作用模式研究。本文提供的筛选途径可能鉴定出新的化学支架,这些化学支架可以作为治疗脑炎甲病毒感染的药物,包括东方或西方马脑炎病毒。因此,这个项目的成功成果将使公众和军队受益,这是与MLPCN和NIH一致的目标。
英文摘要
DESCRIPTION (provided by applicant): This project seeks to discover small molecules active in inhibiting replication of Venezuelan Equine Encephalitis Viruses (VEEV), by utilizing a high throughput screening (HTS) campaign from the Molecular Library Program Center Network (MLPCN). VEEV, an encephalitic alphavirus, is listed as a select agent for its ability to cause severe disease during epidemics as well as its potential use a bioterror weapon. However, there is no FDA-approved treatment or prophylaxis of VEEV-related diseases at this time. Antiviral drug discovery for select agents has been impractical due to restrictions on handling the agents. Progress has been made toward the goal of efficacious treatment by developing a robust cytopathic effect (CPE)-based assay employing an attenuated VEEV strain, TC-83. The attenuated strain is not a select agent and can be handled in a BSL-2 lab. Because the attenuated strain has a significantly high homology between its genome sequence and the wild type VEEV, I hypothesize that the anti-viral compounds screened through this assay would be active for wild type VEEV as well. Thus the result of achieving the specific aims will be assays that can be used as a primary screen to discover active compounds from the Molecular Libraries Small Molecule Repository (MLSMR) library and the follow-up studies to verify activities for the attenuated and wild type virus strains. The first specific aim will be to screen the MLSMR library with a verified, cell-based assay measuring CPE caused by VEEV, strain TC-83 as a primary HTS. The second specific aim will be to verify the selected compounds from the primary screen in two ways 1) a dose-response cytotoxicity and efficacy assay and 2) re-screening with second attenuated strain, V3526 which has a higher similarity with wild types. Finally, a third battery of assays will be provided those are crucial for developing and characterizing chemical probes. The selected compounds will be subsequently verified using titer reduction assays with the wild-type strain, V3000. Last, for the compounds selected as probes, mode of action studies will be performed with reporter- based, molecular and biochemical assays. The screening pathway provided here may identify novel chemical scaffolds that can be pursued as therapeutics for encephalitic alphavirus infections including Eastern or Western equine encephalitis viruses. . Hence successful outcomes from this project will benefit the public and military, a goal that aligns with the MLPCN and the NIH.
PUBLIC HEALTH RELEVANCE: Venezuelan Equine Encephalitis Virus (VEEV) is transmitted to humans and equine by mosquitoes and represents neuroinvasive diseasees. In general, disease is rare in US however epizootic strains of VEEV infected horses and approximately 70,000 ~ 100,000 people in South America in last epidemics in 1995 - 1996. There have also been reports of aerosol transmission of VEEV. VEEV has been weaponized and is a CDC/NIAID category B select agent for biodefense research. Despite of the importance in medical and bioterror needs, there are no treatments for VEEV infection. There is a need for new assays to identify compounds that inhibit VEEV replication. This work represents an unmet medical need for re-emerging viruses which has classified as a select agent. Of importance, Western, Eastern and Venezuelan equine encephalitis viruses are close in a phylogenetic analysis therefore successful outcomes from the proposed project will enlighten the way of discover potential therapeutics for important select agents which are closely related each other.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Project 5: Pandemic Virus Helicase Inhibitors
-
批准号:10522814
-
项目类别:
-
资助金额:$495.13万
-
财政年份:2022
-
负责人:Donghoon Chung
-
依托单位:
Project 5: Pandemic Virus Helicase Inhibitors
-
批准号:10674237
-
项目类别:
-
资助金额:$45.68万
-
财政年份:2022
-
负责人:Donghoon Chung
-
依托单位:
In Vitro Evaluation and Characterization of Novel Lead Therapeutic Candidates for Encephalitic Alphavirus Treatment
-
批准号:10359716
-
项目类别:
-
资助金额:$461.21万
-
财政年份:2019
-
负责人:Donghoon Chung
-
依托单位:
In Vitro Evaluation and Characterization of Novel Lead Therapeutic Candidates for Encephalitic Alphavirus Treatment
-
批准号:10116267
-
项目类别:
-
资助金额:$47.69万
-
财政年份:2019
-
负责人:Donghoon Chung
-
依托单位:
In Vitro Evaluation and Characterization of Novel Lead Therapeutic Candidates for Encephalitic Alphavirus Treatment
-
批准号:10563180
-
项目类别:
-
资助金额:$54.59万
-
财政年份:2019
-
负责人:Donghoon Chung
-
依托单位:
Lead Optimization of ML336, a Potent VEEV Inhibitor
-
批准号:9460361
-
项目类别:
-
资助金额:$65.55万
-
财政年份:2015
-
负责人:Donghoon Chung
-
依托单位:
A Cell-based HTS to discover molecules that inhibit VEEV, encephalitic alphavirus
-
批准号:8070241
-
项目类别:
-
资助金额:$3.73万
-
财政年份:2011
-
负责人:Donghoon Chung
-
依托单位:
In Vitro Evaluation and Characterization of Novel Lead Therapeutic Candidates for Encephalitic Alphavirus Treatment
-
批准号:9886199
-
项目类别:
-
资助金额:$48.98万
-
财政年份:--
-
负责人:Donghoon Chung
-
依托单位:
海外基金